This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.
Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Company undertakes no duty to update these forward-looking statements.
No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.
Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.
2
Key Elements to Build a Global Leader in TCR-based Immunotherapies
Immatics' proprietary platforms create a leadership position in the TCR therapeutics space
Two highly differentiated technology platforms for the discovery of pHLA targets & T cell receptors
• Foundation to achieve the next advance in immunotherapy, particularly for solid tumors
Platforms validated by multiple strategic collaborations with oncology-focused global leaders incl. Amgen, Genmab, BMS, GSK and MD Anderson Cancer Center
Immatics is advancing a proprietary pipeline of Adoptive Cell Therapies (ACT) & TCR Bispecifics
• Four ACT programs in clinical development covering a broad range of solid cancers
• Two TCR Bispecifics programs with off-the-shelf availability in advanced preclinical development
Next-Generationpersonalized multi-target approach designed to achieve durable clinical responses
Immatics builds on sustainable fundamentals
• Strong IP estate & worldwide rights retained on lead programs
~$253m proceeds from Arya/Immatics transaction July 2020 leading to $330m of cash on the balance sheet at the public debut and a cash runway of 3+ years
3
Making a Difference - Delivering the Power of T cells to Cancer Patients
Discovering Targets beyond the Cancer Cell Surface to Unlock Immunotherapies for Solid Cancers
CAR-T and Antibody-based
Approaches
CAR-Tsuccessful in hematological indications but not in solid cancers
Major limitation: targetingsurface proteins on cancer cells, only constituting approx.
25% of the proteome
TCR-based Approaches
T cell receptors (TCRs) accessintracellular targets displayed as peptides on cell surface through HLA receptors
pHLA targets represent the entire proteome, an approx. 300% increased cancer target space vs. CAR-T and antibody-based approaches
Immatics ownssingular technologies to discover pHLA targets and TCRs to unlock immunotherapies for solid cancers
Adapted from Chandran et al., 2019
4
Proprietary Pipeline of Adoptive Cell Therapy (ACT) & TCR Bispecifics
Developing Novel Treatments Across Two Distinct Therapeutic Modalities
5
Recent Major Strategic Collaborations with World-leading Industry Players
Validation of Immatics' Unique Technologies and Expertise
2017
"Developing Novel Bispecific Cancer Immunotherapies"
2 Immatics targets
Immatics XPRESIDENT®, XCEPTOR™ and TCER™ technologies
$30m upfront
Focus on development of
Bispecifics
2018
"Next Generation Bispecific Cancer Immunotherapies"
3 Immatics targets
Immatics XPRESIDENT®, XCEPTOR™ and TCER™ technologies
$54m upfront
Focus on development of
Bispecifics
2019
"Strategic Collaboration to Develop Novel ACT"
3 Immatics targets
Immatics XPRESIDENT®, XCEPTOR™ and ACTengine® technologies
$75m upfront
Focus on development of Adoptive Cell Therapies
2020
"Strategic Collaboration to Develop Next-generation TCR Therapeutics"
2 Immatics targets
Immatics XPRESIDENT®, XCEPTOR™ and ACTengine® technologies
$50m upfront
Focus on development of Adoptive Cell Therapies
6
Immatics - Delivering the Power of T cells to Cancer Patients
IDENTIFY
DELIVER
PIONEER
True Targets
Therapeutic Pipelines
Multi-Target Personalized
and Right TCRs
of ACT and TCR Bispecifics
Precision Immunotherapy
Two Proprietary Technology Platforms
Two Distinct Modalities
Personalized & Precise
as foundation for the next advance
building a diverse
Product candidates against multiple individual
in immunotherapy,
preclinical and clinical pipeline
well characterized pHLA targets
particularly for solid tumors
Adoptive Cell Therapies
Proprietary XPRESIDENT®-AI
XPRESIDENT®
ACTengine® (TCR-T)
for full antigenic profiling and target selection
Target Discovery
ACTallo® (Next-generation)
of any individual tumor
>200 prioritized targets
TCR Bispecifics
Multi-Target/ TCR
XCEPTOR™
TCER™ - Off-the-shelf Biologics with
ACTolog® pilot study for multi-target ACT
TCR Discovery,
distinct attributes for use at
Building ACTengine® warehouse for
Engineering and Validation
an earlier disease stage
multi-targetTCR-T
7
Discovery of True Cancer Targets - XPRESIDENT® Technology Platform
Prioritization of >200 pHLA Targets Covering All Target Classes
pHLA DATABASE
based on primary tissues
Cancer tissues
20major
indications
&
>2,000 cancer & normal
>200
tissues analyzed by
prioritized
Normal tissues
Quantitative MS
targets
40tissue types
covering all
major organs
TARGET CLASSES
Well known and characterized parent proteine.g. MAGE family cancer testis antigens
Immatics' clinical frontrunner targets show specificity profiles similar to NY-ESO-1
while having significantly higher peptide copy numbers
1 Natural presentation of this peptide has been validated by clinical data, 2 Validated by XPRESIDENT® mass spectrometry. Target peptide copy numbers per cell were determined by AbsQuant™ technology, 3 Internal specificity categorization used at Immatics.
Specificity class 1: peptide not routinely found on any normal tissue; no relevant RNA expression detected on critical organs, Specificity class 2: peptide showing a large therapeutic window with rare detections on normal tissue and low RNA expression on critical organs. 12
4 Purbhoo et al., J Immunol 176:7308-7316 (2006), 5 Robbins et al., J Clin Onco 29(7): 917-924 (2011). Target prevalences for ACTengine® targets are based on TCGA data combined with a XPRESIDENT®-determined target individual MS-based mRNA expression threshold.
ACTengine® - Optimized Manufacturing
Established cGMP Capacities to Advance Next-Generation Cell Manufacturing Developments
Leukapheresis
Infusion-Ready
Manufacturing for ongoing ACT programs
Proprietary short manufacturing process designed to produce phenotypically younger, better persisting T cells
T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth, inHouston, TX
1,850 square foot state-of-the-artcGMP Facility operated by Immatics personnel
Capacity: up to 48 manufacturing runs/month
13
ACTengine® - Initial Biological Data
Initial Data from IMA201, IMA202 and IMA203 as of 1Q 2020
Studies Enrollment Status
Products successfully manufactured for 10/10 patients
First 4 patients treated across IMA201, IMA202 and IMA203 trials at lowest dose of dose escalation scheme(50 million specific T cells/m² 5-10% of anticipated target dose at end of dose escalation)
Preliminary Biological Activity and Safety Data
Very high frequencies of persisting circulating target-specific T cells observed at lowest infused dose (up to 45%)
Current longest observation period is 12 weeks - during this time T cells persist
Serial biopsy analysis demonstrates infiltration of target-specific T cells into post-treatment tumor biopsies
ACTengine® treatment is well-tolerated to date with no changes to treatment regime required
Next combined data read-out expected in 1Q 2021
Cellular Immunomonitoring in Blood
Molecular Immunomonitoring in Blood
Molecular Immunomonitoring in Tumor
IMA203 Patient #1
Vector copies/ug gDNA
1×106
1×105
1×104
1×103
1×102
1×101
1×100
201 Pt #1
202 Pt #1
203 Pt #1
202 Pt #2
IMA202 Patient #2, IMA203 Patient #1
IMA202 Pt#2
IMA203 Pt#1
Baseline
Day
1
3
1
2
3
4
8
12
Week
Day Week Week Week Week Week
Visit
January 2020
14
ACTallo® - Next Generation Off-the-shelfTCR-T Therapy
Allogenic, Genetically Modified γδ T cells Expressing a Novel TCR
Proprietary manufacturing expands
ACTallo® T cells rapidly to large numbers
HLA-A*02
positive
γδ T cells
Areabundant in the peripheral blood
Show intrinsic anti-tumor activity
Naturally infiltratesolid tumors and correlate with favorable prognosis
Are HLA-independent, thus do not cause GvHD in allogenic setting
Can be expanded rapidly to high numbers in a cGMP-compliant manner
Can be effectively redirected usingαβ TCR or CAR constructs
Are promising for an off-the-shelf cell therapy approach
15
TCER™ - Immatics' TCR Bispecifics
Mode of Action
16
TCER™ - Engineering an off-the-shelf Biologic
Adoptive Cell Therapy
TCR Bispecifics
ACTengine®
T cell engaging
ACTallo®
receptor (TCER™)
Proprietary XCEPTOR™ Platform
Natural or optimized natural TCR
TCR Discovery,
with micromolar affinity and
Engineering and Validation
favorable specificity profile
Fast and efficient discovery of
for genetic engineering of
multiple TCRs per target
autologous and allogeneic T cells
Unique XPRESIDENT®-guidedon-
and direct clinical application
and off-target toxicity screening
to deselect cross-reactive TCRs
Affinity-maturatednatural
TCR variable domains with nanomolar affinity and favorable specificity profile
XPRESIDENT®-guided
similar peptide counterselection
during maturation
Highly potent TCR Bispecifics format with
extended half-lifeand antibody-like
stability and manufacturability
17
TCER™ - Summary IMA401 Lead Candidate
Proprietary TCR Bispecifics Format
TCER™ design confers superior potency and stability compared to multiple tested alternative bispecific formats
Significantly extended half life of several daysas compared to competitor molecules
Very High Potency
Very low concentration (low pM range) required for invitro killing of tumor cells expressing physiological levels of target pHLA
Complete tumor eradicationin vivo (tumor xenograft mouse model)
Distinguished Specificity
Broad therapeutic window (≥ 1,000 - 10,000 fold) as defined by reactivity against tumor cells and healthy tissue cells
Favorable CMC Characteristics
Excellent manufacturability in CHO cells
Very stable compound (stress testing in PBS)
Patient Population
Target-positivesolid tumors, including cancers of the lung, head and neck, esophagus, sarcoma and several others
Tumor Xenograft Mouse Model
Study day -21: transplantation of tumor cells
Study day 0: human PBMC transplantation & start of treatment
18
Immatics - Delivering the Power of T cells to Cancer Patients
IDENTIFY
DELIVER
PIONEER
True Targets
Therapeutic Pipelines
Multi-Target Personalized
and Right TCRs
of ACT and TCR Bispecifics
Precision Immunotherapy
Two Proprietary Technology Platforms
Two Distinct Modalities
Personalized & Precise
as foundation for the next advance
building a diverse
Product candidates against multiple individual
in immunotherapy,
preclinical and clinical pipeline
well characterized pHLA targets
particularly for solid tumors
Adoptive Cell Therapies
Proprietary XPRESIDENT®-AI
XPRESIDENT®
ACTengine® (TCR-T)
for full antigenic profiling and target selection
Target Discovery
ACTallo® (Next-generation)
of any individual tumor
>200 prioritized targets
TCR Bispecifics
Multi-Target/ TCR
XCEPTOR™
TCER™ - Off-the-shelf Biologics with
ACTolog® pilot study for multi-target ACT
TCR Discovery,
distinct attributes for use at
Building ACTengine® warehouse for
Engineering and Validation
an earlier disease stage
multi-targetTCR-T
19
ACTolog® - Pioneering Personalized Multi-target T cell Therapy
Pilot Trial Using Autologous T cells Expressing Endogenous TCRs
Lymphodepletion (Flu/ Cy)
T cell infusion Low dose IL-2
Personalized multi-target T cell product against selected targets
HLA-A*02
positive
Cancer
Biopsy: Biomarker profiling
patient
x x x x
ACTolog® target warehouse
Leukapheresis
Selection of up to 4 targets
expressed on tumor
ACTolog® IMA101
Approach
• Personalized multi-target T cell therapy
using a warehouse approach
• Autologous T cells, Endogenous TCRs
• Clinical proof of concept previously
delivered in melanoma by Cassian Yee
(MD Anderson Cancer Center) with
single target in combination with
checkpoint inhibition [Chapuiset al., Sci
Transl Med (2013) and Chapuis et al., JCO (2016)]
Indications• Basket trial in solid tumors
First-in-humantrial ongoing
Study
• Cohort 1
(ACTolog® only)
Design/
•
Cohort 2
(plus Atezolizumab)
Status
•
Total of N=12 patients treated as of
January 2020, up to N=20 planned
T cell manufacturing: priming and expansion
The ACTolog® program is supported by a grant of the Cancer Prevention & Research Institute of Texas (CPRIT)
20
ACTolog® - Pioneering Personalized Multi-target T cell Therapy
Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 2-12).
Very high ACTolog® cell doses (mostly >1010) could be administered.
Patients received mostly multi-target ACTolog® products (range 1-3).
ACTolog® has led to high target specific T cell levels and persistence with total frequencies up to 80% of all peripheral CD8+ T cells.
T cells exhibit a non-exhausted phenotype.
Target specific T cells were detectable in post-treatment tumor biopsies
Safety
Assessment
Preliminary
Clinical
Assessment
ACTolog® IMA101 is well-tolerated to date with no changes to treatment regime required.
The most common adverse events were expected cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome.
Patients entered the trial with progressive disease, having failed the previous line of therapy.
Median time to progression was ~12 weeks (range 6 weeks to 7 months) by RECIST1.1 (in some cases with transient tumor reduction of up to 26%).
21
Immatics' Multi-targetTCR-T Strategy and Vision
Addressing Major Challenges in Immuno-oncology to Make a Therapeutic Difference
1
2
3
4
ACTolog®
7 Immatics' targets
Screening completed
ACTengine®
IMA201-204
1 target/ TCR per trial
Trials recruiting
Initial ACTengine® warehouse
TCR combination trials
Multi-TCR warehouse
XPRESIDENT® Target Pool
IMA201-204 Warehouse
Extended Immatics TCR
Warehouse
Mission to treat every patient
ACTolog® = Multi-target Cell Therapy PILOT study
Delivered initial clinical data 2019
ACTengine® BLA filing(s)
for single TCR in specific indications (incl. niche)
Personalized Multi-targetTCR-TBLA filing of ACTengine® warehouseor single TCRs
e.g. IMA204 stroma targeting plus IMA201-203 tumor targeting
Single or Multi-target
Simultaneous targeting
TCR-T product
of tumor & stroma
Next generation efficacy
Overcoming tumor
heterogeneity and
enhancing technologies
tumor escape
(e.g. CD4 T cells, gene editing)
Overcoming the
Smart combination therapy
inhibitory tumor
microenvironment
22
The Leadership Team
Experienced Global Leadership Team Across Europe and the US
Harpreet Singh
Rainer Kramer
Chief Executive Officer
Chief Business Officer
Thomas Ulmer
Steffen Walter
Chief Financial Officer
Chief Technology Officer
Carsten Reinhardt
Cedrik Britten
Chief Development Officer
Chief Medical Officer
Toni Weinschenk
Jordan Silverstein
Chief Innovation Officer
Head of Strategy
23
Strong, Focused and Highly Integrated Trans-Atlantic Organization
United to Build a Global Leader in T cell Receptor-based Immunotherapies
Tübingen, Germany, 120 FTEs
Senior Leadership, Research and
Development (XPRESIDENT®,
XCEPTOR™, TCER™), Translational
Development, Clinical Operations,
Finance, HR, IT, QM
Munich, Germany, 10 FTEs
Houston, Texas , 70 FTEs
Senior Leadership, Research and
Development (Adoptive Cell Therapy),
CMC, Clinical Operations, Regulatory
Affairs, QA/QC, HR, Investor Relations
Senior Leadership, Business Development,
Intellectual Property, Regulatory Affairs,
Communications
24
Continuously Growing IP Portfolio Protecting Proprietary Know-How
Immatics' Patent Estate - Territorial Coverage
• ~ 5000 applications and patents
• >100 patent families
IP protection on >8000 cancer targets, TCRs and technology
Immatics files patent applications in all major countries and regions
>230 granted patents in the US
>15 granted patents in Europe
>1550 granted patents overall
25
Immatics & ARYA Transaction Highlights
Transaction
Summary
Premier
Specialist
Investor Base
Use of
Proceeds
Key
Management
and Board
The business combination transaction with Perceptive Advisors' sponsored SPAC - Arya Sciences Acquisition Corporation - was completed on July 1st, 2020
The combined company, renamed Immatics N.V., starts trading its shares under the ticker symbol "IMTX" on the Nasdaq
Proceeds from the transaction were approx. $250 million, combining funds held in Arya's trust account and a PIPE financing
The shareholders of Arya and Immatics approved the transaction on June 29th, with no Arya shareholder redemptions
Common shares outstanding: 63,383,750
Immatics existing investor base (including dievini, AT Impf, Wellington Partners, MIG) continues to support the company
The shareholder base will be extended by premier US investors including Perceptive Advisors, Redmile Group, Federated Hermes Kaufmann Funds, RTW Investments, Sphera Funds as well as previous SPAC shareholders
A total of ~$253m including proceeds from the ~$104m PIPE financing as well as ~$149m Arya trust proceeds
Funding is expected to primarily be used for clinical programs and technology advancements, including ACTengine®, Next-Gen ACT and TCER™ technology
Funds are expected to provide runway into mid 2023
Combined company is led by Immatics Chief Executive Officer, Harpreet Singh, Ph.D.
Board of Directors is consisting of experienced executives from the life sciences sector
26
Milestones to Achieve the Next Advance in Immunotherapy
Immatics' Achievements to Date
>200 prioritized targets
Eight proprietary pipeline programs, four of them in clinical development
ACT: Early clinical data obtained in 2019 demonstrating biological activity
TCR Bispecifics: Manufacturing activities started for Lead Candidate
Collaborations with global leaders in the field of immuno-oncology including GSK (2020),
BMS (2019), Genmab (2018) & Amgen (2017)
Near-Term Value Inflection Points
Projected major value inflections 2020-2021 are expected to lead to a significant valuation step up
ACTengine®
Next combined clinical data read-out for IMA201, 202 and 203 trials in 1Q 2021
IND for IMA204 program in 2021
TCER™
IND for the first TCER™ program IMA401, YE 2021
Preclinical proof of concept for IMA402
Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific
targets and TCRs to advance the pipeline of Adoptive Cell Therapy and TCR Bispecifics.
27
Combining Key Elements to Become a Leading TCR Company
Proprietary
Foundation
Programs in
Development
Sustainable
Fundamentals
2
>200
True targets
2
>1,550
Technology platforms
&
for the discovery of
prioritized cancer
Distinct Therapeutic
granted patents
targets
Right TCRs
Modalities
pHLA targets & TCRs
ACT & TCR Bispecifics
4
2
10
Pioneering
ACT programs in clinical
development programs in
Next-gen Technologies
development
IND filings expected
collaborations with global
Novel Targets
industry leaders incl.
with data read-out expected in
in 2021
Off-the-shelf ACT
GSK, BMS, Genmab,
Multi-target personalized ACT
2020/early 2021
Amgen
~$330m
>200
A fully integrated
>63m(1)
Employees
1,850 sq. ft.
IMTX
Cash
in Europe
cGMP site operational in
Shares outstanding
No debt
& the US
Houston, TX
(1) plus ~7.2m warrants plus ~6.8m options
28
Thank you
www.immatics.com
Please contact us via partnering@immatics.com to learn more about partnering and licensing opportunities utilizing our platform technologies XPRESIDENT®, XCEPTOR™, IMADetect™ and AbsQuant™. 29
Immatics NV published this content on 09 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2020 08:50:08 UTC
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
